Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. The Food ...
SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults. SK Life Science has announced the availability of Xcopri ...
The FDA recently approved XCOPRI for adults with partial-onset seizures, its manufacturer announced. “The approval of XCOPRI will provide clinicians with an effective medication for our patients who ...
The Food and Drug Administration on Wednesday approved Eisai’s epilepsy drug Fyompa as a primary treatment for partial-onset seizures in epileptic patients 12 years or older. Here are three things to ...
child yellow pill medicine Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing. The Food and Drug Administration has expanded ...
Forbes contributors publish independent expert analyses and insights. I focus on new drugs and innovations in medical devices. Last week, the FDA approved XCOPRI (cenobamate tablets) to treat ...
Dec. 12, 2002 — At the 56th annual meeting of the American Epilepsy Society, three reports of open-label testing of oxcarbazepine (Trileptal) suggest that the drug is safe and effective in adults and ...
Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...
If your child has a seizure, it's natural to have plenty of concerns about what exactly happened, why, and what comes next. There are treatments that can help, but a lot depends on the cause of the ...
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the antiepileptic lacosamide UCB (UCB Pharma SA) for partial-onset ...
The FDA has approved an expanded indication for Briviact CV tablets, oral solution and injection, for treating partial-onset seizures among children as young as 1 month. “When a child or infant ...
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration (FDA) for an indication expansion for Eisai's antiepileptic drug (AED) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback